BridgeBio Pharma and Eidos Therapeutics Announce Merger Agreement; Eidos Stockholders Will Have The Right To Receive In The Transaction, At Their Election, Either 1.85 Shares Of Bridgebio Common Stock Or $73.26 In Cash Per Eidos Share In The Transaction